Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

28.51 -0.92 (-3.13%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2026 Add to My Watchlist

Price and Volume

Volume	2,638,957
Open	29.00
Bid (Size)	26.50 (100)
Ask (Size)	29.43 (1,000)
Prev. Close	29.43
Today's Range	28.07 - 29.52
52wk Range	12.00 - 29.96
Shares Outstanding	144,311,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

September 25, 2026

Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cells

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

September 17, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Performance

YTD	+79.2%	+79.2%
1 Month	+14.4%	+14.4%
3 Month	+33.2%	+33.2%
6 Month	+121.9%	+121.9%
1 Year	+111.8%	+111.8%

More News

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 01, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies Q2 Earnings Call Highlights ↗

July 29, 2026

Via MarketBeat

Adaptive Biotechnologies (NASDAQ:ADPT) Surges After Q2 Beat and Raised Guidance ↗

July 29, 2026

Via Chartmill

Adaptive Biotechnologies (NASDAQ:ADPT) Surges 6% on Q1 Beat and Raised MRD Guidance ↗

May 05, 2026

Via Chartmill

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

July 29, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run ↗

July 12, 2026

Via The Motley Fool

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

July 09, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

June 17, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

June 15, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

June 15, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors? ↗

June 14, 2026

Via The Motley Fool

Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference ↗

June 03, 2026

Via MarketBeat

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

May 29, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million ↗

May 26, 2026

Via The Motley Fool

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

May 21, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive (ADPT) Q1 2026 Earnings Transcript ↗

May 06, 2026

Via The Motley Fool

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

May 05, 2026

Via Chartmill

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

May 05, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. ↗

May 04, 2026

Via The Motley Fool

Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means ↗

April 20, 2026

Via The Motley Fool

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? ↗

April 18, 2026

Via The Motley Fool

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

April 15, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On ↗

April 08, 2026

Via The Motley Fool

Frequently Asked Questions

Is Adaptive Biotechnologies Corporation - Common Stock publicly traded?

Yes, Adaptive Biotechnologies Corporation - Common Stock is publicly traded.

What exchange does Adaptive Biotechnologies Corporation - Common Stock trade on?

Adaptive Biotechnologies Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Adaptive Biotechnologies Corporation - Common Stock?

The ticker symbol for Adaptive Biotechnologies Corporation - Common Stock is ADPT on the Nasdaq Stock Market

What is the current price of Adaptive Biotechnologies Corporation - Common Stock?

The current price of Adaptive Biotechnologies Corporation - Common Stock is 28.51

When was Adaptive Biotechnologies Corporation - Common Stock last traded?

The last trade of Adaptive Biotechnologies Corporation - Common Stock was at 09/28/26 04:00 PM ET

What is the market capitalization of Adaptive Biotechnologies Corporation - Common Stock?

The market capitalization of Adaptive Biotechnologies Corporation - Common Stock is 4.11B

How many shares of Adaptive Biotechnologies Corporation - Common Stock are outstanding?

Adaptive Biotechnologies Corporation - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.